Regeneron
FDA Authorizes REGEN-COV for Post-Exposure Prophylaxis for COVID-19
The FDA revised the EUA for casirivimab and imdevimab, the Regeneron cocktail for post-exposure prophylaxis (PEP) ...
AUGUST 3, 2021
Cost of Praluent PCSK9 Inhibitor Lowered for Medicare Patients
The cost of Praluent, regardless of dose, will be $5,850 annually, a 60% reduction from the original price.
FEBRUARY 12, 2019
FDA Approves New Indication for Dupixent for Asthma
Dupilumab inhibits the overactive signaling of IL-4 and IL-13, two key proteins that contribute to the Type 2 ...
OCTOBER 20, 2018
FDA Approves Libtayo as First and Only Treatment for Advanced CSCC
Libtayo is a fully human monoclonal antibody that targets the immune checkpoint receptor PD-1 and works by blocking ...
SEPTEMBER 28, 2018
Amgen Wins Next Step in Patent Dance Over PCSK9 Drugs
Despite the win, the case is long from over; Sanofi and Regeneron plan to appeal.
MARCH 24, 2016
